4//SEC Filing
NEIS JOHN 4
Accession 0001104659-25-121691
CIK 0001279704other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 6:00 PM ET
Size
6.4 KB
Accession
0001104659-25-121691
Insider Transaction Report
Form 4
NEIS JOHN
Director
Transactions
- Sale
Common Stock
2025-12-12$3.70/sh−198$732→ 10 total(indirect: See Footnote)
Footnotes (3)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.631 to $3.70, inclusive. The reporting person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote (1) to this Form 4.
- [F2]This number has been adjusted for (i) the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025, (ii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022, and (iii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 16, 2018.
- [F3]These securities are held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture Investors LLC are made collectively by five managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein.
Documents
Issuer
Cellectar Biosciences, Inc.
CIK 0001279704
Entity typeother
Related Parties
1- filerCIK 0001167426
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 6:00 PM ET
- Size
- 6.4 KB